Letter: budesonide for functional dyspepsia with duodenal eosinophilia-randomised, double-blind, placebo-controlled parallel-group trial

N J Talley; M M Walker; M Jones; S Keely; N Koloski; R Cameron; T Fairlie; G Burns; A Shah; T Hansen; G Harris; G Holtmann

doi:10.1111/apt.16396

Letter: budesonide for functional dyspepsia with duodenal eosinophilia-randomised, double-blind, placebo-controlled parallel-group trial

Aliment Pharmacol Ther. 2021 Jun;53(12):1332-1333. doi: 10.1111/apt.16396.

Authors

N J Talley^{1

2}, M M Walker^{1

2}, M Jones^{2

3}, S Keely^{1

2}, N Koloski^{1

2

3

4}, R Cameron^{1

2}, T Fairlie⁴, G Burns^{1

2}, A Shah^{2

4

5}, T Hansen³, G Harris^{1

2}, G Holtmann^{2

4

5}

Affiliations

¹ University of Newcastle, Newcastle, NSW, Australia.
² NHMRC Centre of Research Excellence in Digestive Health, New Lambton Heights, NSW, Australia.
³ Department of Psychology, Macquarie University, Ryde, NSW, Australia.
⁴ Department of Gastroenterology, Princess Alexander Hospital, Woolloongabba, Qld, Australia.
⁵ School of Medicine, University of Queensland, St Lucia, Qld, Australia.

PMID: 34029411
DOI: 10.1111/apt.16396

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Budesonide / therapeutic use
Double-Blind Method
Dyspepsia* / drug therapy
Eosinophilia* / drug therapy
Gastroesophageal Reflux*
Humans

Substances

Budesonide